the Salk-type vaccine was adequately used.'8 * It is the only vaccine at present approved as a method for the prevention of paralytic poliomyelitis in the United States. Its potency has been improved recently, and the gains which have been made in reducing the incidence of paralytic poliomyelitis are almost certain to continue. On these bases the Salk-type vaccine deserves vigorous support, and campaigns to extend its use are distinctly in order. Nevertheless, as with most such prophylactic and therapeutic measures, techniques are liable to change. Thus there are questions not only with regard to the ways of giving the Salk-type vaccine but also as to whether it will be eventually replaced by a live poliovirus vaccine, or conceivably whether there will be some sort of combination of the two."' The ultimate aim is, and has been, of course, to reduce paralytic poliomyelitis to the lowest possible minimum.
The case for the live poliovirus vaccine rests in part upon the idea that an actual induced infection will produce a more solid type of immunity than will the parenteral injection of a killed viral antigen. This suggests that the Salk-type vaccine is not quite adequate and so one should first look at the record of the past four years in which the Salk-type vaccine has been used in the United States. In some areas in 1959 the efficiency of the killed vaccine in protecting against paralytic poliomyelitis has been rated as high as 90 per cent. And yet troublesome epidemics of poliomyelitis occurred in certain U. S. cities in 1958 and 1959, the latter having been a relatively bad year with more than 5,000 paralytic cases as of December 1959. Before criticizing the potency of the killed vaccine, it should be pointed out that the major reason why paralytic poliomyelitis has not been more markedly reduced, has been the failure, during the past four years, of many to take advantage of the vaccine for themselves or for their children. The vaccine itself cannot be blamed for this. In many U. S. cities not more than half the population under 40 years of age has been vaccinated and in the serious U. S. epidemics of 1958 and 1959 most of those who contracted paralytic poliomyelitis either had not been vaccinated at all or had been inadequately vaccinated. For example, in the Detroit epidemic of 1958, only 12 per cent of the paralytic cases occurred in persons who had received three doses of vaccine, whereas 73 per cent of such * Current techniques for the administration of this vaccine call for its intramuscular inoculation in three divided doses of 1 ml. each, the second being given one month to six weeks after the first, and the third not earlier than seven months after the second.
To increase the efficiency of the vaccine, the Surgeon General of the U.S. Public Health Service recommended in June 1959 that a fourth dose might be given one year after the third. There has even been some discussion as to the possibility of recommending a subsequent annual dose to children, but no definitive opinion has been reached on this point which is for the future to decide. cases occurred in persons who had received no vaccine." In particular, it has been among infants and young children below the age of six years and young adults between 18 and 40 where the vaccination program has lagged. To meet these deficiencies in the United States much attention is being brought to bear on this problem by municipal, state, and national health services.
In reviewing indications for the use of the Salk-type vaccine one should consider the way that it is supposed to work, namely, that by inoculating killed poliovirus into the body a certain degree of immunity is created which protects the person against a subsequent severe infection with live, virulent poliovirus. One should recall in this connection that ordinarily almost 99 per cent of natural infections with live virulent poliovirus are so mild as to escape notice. This is the way (i.e., from repeated mild, inapparent infections) that most people before the days of vaccination gained their immunity. In some persons, however, the infection with poliovirus is severe enough to cause paralysis and this is the risk that unvaccinated people take. Thus the Salk-type vaccine does not prevent mild infections with polioviruses. Its effect is to keep the immunity of the person who has been vaccinated at such a level that when he does become infected, his "case" will be mild. infection than from the injection of a killed substance into the body. Obviously, this last statement needs qualification, because one could continue injecting killed substances into a given person, month after month or year after year, thereby producing a very solid kind of immunity, but such a procedure would not be very practical. The problem then in the progran for the control of paralytic poliomyelitis is to see, first, whether the domesticated (so-called attenuated) polioviruses now being proposed to be used as vaccines by Dr. Koprowski, Dr. Sabin, and Dr. Cox are safe; and, secondly, whether they will confer a solid kind of immunity on the person thus vaccinated-at least as solid if not more so than that produced by the killed poliovirus vaccine.
The principle of this type of vaccination is obviously similar to that of vaccination against smallpox, namely, by inducing an actual though harmless infection with a live, a virulent virus, related to that which causes the serious disease, one also induces immunity to the serious disease. As the natural portal of entry of poliovirus is through the alimentary tract, the live poliovirus vaccines are administered by mouth instead of by injection. Thus they might serve as agents which should be more easily administered. They will probably be less expensive. However, whether or not they are practical and more efficient remains to be seen.
There is evidence that the kind of immunity induced by the killed Salktype vaccine may differ from that of the live poliovirus vaccines. With the former it is assumed that adequate neutralizing antibody levels are a measure of the immunity produced and that they reflect something that limits the spread of poliovirus within the body, thereby preventing significant invasion of the central nervous system. There is less evidence, however, that such circulating antibodies are a measure of resistance against subsequent implantation of the virus or penetration of the virus through the superficial or deeper layer of the integument of the alimentary tract. Thus the presence of artificially induced antibodies of moderate levels in itself does not prevent subsequent alimentary infection. With the live poliovirus vaccines, antibodies are also produced which circulate in the blood stream, but evidence suggests that in addition there is produced some kind of tissue resistance, or locally concentrated humoral resistance, to which the term "local resistance" might be applied until a better name is suggested. In any event, a person vaccinated (i.e., actually infected) with live attenuated poliovirus is more apt to have developed a state of resistance for the prevention of a reinfection with virulent polioviruses than is the person who has received killed virus. Re-infections nonetheless do occur.
So far the attenuated poliovirus vaccines have certain advantages, but there are complexities in their use still to be unravelled and they are still to be regarded, as far as the U. S. Public Health Service is concerned, as being in an experimental stage. One feature is that the live virus vaccine does not always take and it is not easy to know when this happens. Another is that anyone acutely infected with these viruses may spread the infection to others in much the same manner that anyone with a cold might infect his intimate associates. Thus involuntary vaccination may result, and it is easy to see how there could be opposition on the part of the public to this idea, perhaps comparable to the kind of objection occasionally encountered about putting fluorides in the water supply.
As to the origin of these attenuated polioviruses, some of them have been produced in the laboratory, others have been picked up in the so-called "wild" state. Those which have been prepared in the laboratory have been subjected to a process of domestication as it were. The most frequently used method of domestication or of taming these strains of virus has been that of starting with a virulent strain of poliovirus and growing it continuously with multiple passages in tissue cultures. What happens under these circumstances is that the dangerous strain of poliovirus in the course of adapting itself to a new and artificial environment may lose the property of virulence. After prolonged transfer of this kind, often by means of the terminal dilution techniques, the assumption has been made that this loss of virulence becomes more or less fixed and the strain of modified virus can be considered relatively safe for use as an immunizing agent in man. Some of the tests employed to check this are measures of the neurovirulence in the monkey on both intracerebral or intraspinal inoculation; there are also a number of other measurable properties more or less related to virulence, but the ultimate tests of safety, and by far the most extensive, have been made on man. In these field trials on human populations, the objective has been to see whether there has been any evidence of illness in those who have received the vaccine, i.e., vaccines, or whether any illness traceable to infection by the attenuated poliovirus has been evident among the vaccinee's neighbors. Surveys have also been made to see whether the domesticated virus may or may not gradually work its way back to being a dangerous virus during the time in which it multiplies within the body of a single person or whether virulence becomes enhanced during natural human-to-human passage. Obviously, if reversion to virulence occurs, this would be an undesirable event. All one can say at present is that illness which has been the proven result of an infection by attenuated poliovirus given as a vaccine has to date not been noted. It has been noted nonetheless that attenuated virus excreted in stools occasionally shows evidence of having undergone some changes and even to have become slightly more virulent than when fed. However, such viruses are still in that attenuated range where they are relatively harmless.
In The results so far seem to be satisfactory and among the millions of persons, including infants, children, and adults, who have received this vaccine to date there has not been a single unfavorable report. Nonetheless, quite a few questions still remain to be answered about the live vaccine. How many individuals, particularly the children who have received the vaccine, are actually immunized as a result of this experience is a question with high priority. It appears that this measure of efficiency differs in different environments. Without laboratory tests it is impossible to determine whether a "take" has occurred or not. Failure to take can be due to several factors. The phenomenon of interference, for instance, can be one of them-interference not only by wild polioviruses but by other enteroviruses. At the present time trials are being conducted to determine whether by increasing the dosage this deficiency can be overcome.
One may ask here, with justification, why is there any need for a new poliomyelitis vaccine if the Salk-type vaccine is successful and will continue to be used and if there are so many unknowns with regard to live poliovirus vaccine? A primary answer to this is that, after all, it is logical that a search for improvements in methods of protecting against this serious disease should continue. As mentioned earlier in this article, the Salktype vaccine has not been found to protect all those to whom it has been given in three doses. In the U.S.A. in 1959 this could amount to 10 or 15 per cent of the 5,000 or more reported paralytic cases. As the ultimate objective is to protect all by methods that will prove practical, a search for improvements should continue. Furthermore, the Salk-type vaccine is still moderately expensive for some countries, notably several in Latin America and elsewhere, which might wish to use this vaccine on a large scale but have claimed that they cannot afford to do so. This may not be a valid criticism, for the cost of the live poliovirus vaccine is as yet an unknown quantity. Another criticism of the Salk-type vaccine is that the way in which it is necessary to give it-two inoculations four to six weeks apart with a third not earlier than seven months later, and a fourth a year after the third dose-is a difficult schedule for some people to follow. The lag in persuading people in the United States to take advantage of the Salktype vaccine and to follow the proper schedule suggests that an equal or greater task might exist in those countries less attuned to the idea of prophylactic inoculations than is the United States. The live poliovirus given by mouth (three times, a month apart, for the monovalent live vaccine or perhaps not more than twice a month or six weeks apart for the trivalent) sounds easier administratively. It may be important to find out whether that fraction of the U. S. population which has refused or failed to take advantage of the Salk-type vaccine will also refuse or not even be interested in the live poliovirus vaccine. Thus it remains to be seen whether the live attenuated poliovirus vaccine will better the record of Salk-type vaccine. The suggestion that it might is a challenge worth accepting. As a hypothetical means of promoting the universal administration of live poliovirus vaccine it has even been suggested, and this is under trial, that following an initial and vigorous campaign in the local use of this vaccine for children and young adults it might then be given to all newborn babies and by this means the immunity of the entire population could consequently be kept up. It remains to be seen whether parents or hospitals would accept this responsibility or indeed whether newborn babies would be sufficiently easily infected. The chances of their having interfering enteroviruses during the first days of life would seem slim but infants may have a natural form of resistance which might be difficult to overcome in order to get a take. It is easy to see how all these important questions demand vigorous attention and extensive trials. In any event, if untoward incidents or deficiencies are to occur, it is far better to have them occur during the trial stage than afterwards when the vaccine has been approved and licensed.
In the meantime it seems unlikely that the people of the United States will quickly abandon the Salk-type vaccine in favor of a new product, particularly as the former is being steadily improved. However, during the next few years at least there may be an increasing use of a combination of the two, i.e., a course of killed vaccine followed by live vaccine. Theoretically this might yield a higher degree of protection than the use of either vaccine alone.
To summarize the present situation, we face the fact that the only recognized and official prophylactic agent against poliomyelitis in the United States is the Salk-type vaccine. Its continued and wider use should not only be encouraged here but urged. The live poliovirus vaccine should be regarded as something of considerable promise which is still in the trial stage. The present results of field trials, some of which have been very extensive, are sufficiently encouraging to indicate that they should proceed with dispatch if this promising new prophylactic measure is to have the widespread use it may ultimately deserve.
